1. Home
  2. KAPA vs SYBX Comparison

KAPA vs SYBX Comparison

Compare KAPA & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KAPA
  • SYBX
  • Stock Information
  • Founded
  • KAPA 2013
  • SYBX N/A
  • Country
  • KAPA United States
  • SYBX United States
  • Employees
  • KAPA N/A
  • SYBX N/A
  • Industry
  • KAPA
  • SYBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KAPA
  • SYBX Health Care
  • Exchange
  • KAPA NYSE
  • SYBX Nasdaq
  • Market Cap
  • KAPA 19.9M
  • SYBX 16.5M
  • IPO Year
  • KAPA 2024
  • SYBX N/A
  • Fundamental
  • Price
  • KAPA $1.63
  • SYBX $1.43
  • Analyst Decision
  • KAPA Strong Buy
  • SYBX Hold
  • Analyst Count
  • KAPA 1
  • SYBX 3
  • Target Price
  • KAPA $9.00
  • SYBX $1.00
  • AVG Volume (30 Days)
  • KAPA 6.1M
  • SYBX 24.4K
  • Earning Date
  • KAPA 02-23-2025
  • SYBX 03-18-2025
  • Dividend Yield
  • KAPA N/A
  • SYBX N/A
  • EPS Growth
  • KAPA N/A
  • SYBX N/A
  • EPS
  • KAPA N/A
  • SYBX N/A
  • Revenue
  • KAPA N/A
  • SYBX $2,777,000.00
  • Revenue This Year
  • KAPA N/A
  • SYBX N/A
  • Revenue Next Year
  • KAPA N/A
  • SYBX N/A
  • P/E Ratio
  • KAPA N/A
  • SYBX N/A
  • Revenue Growth
  • KAPA N/A
  • SYBX 292.23
  • 52 Week Low
  • KAPA $0.85
  • SYBX $1.22
  • 52 Week High
  • KAPA $4.00
  • SYBX $3.73
  • Technical
  • Relative Strength Index (RSI)
  • KAPA N/A
  • SYBX 49.27
  • Support Level
  • KAPA N/A
  • SYBX $1.36
  • Resistance Level
  • KAPA N/A
  • SYBX $1.47
  • Average True Range (ATR)
  • KAPA 0.00
  • SYBX 0.08
  • MACD
  • KAPA 0.00
  • SYBX 0.00
  • Stochastic Oscillator
  • KAPA 0.00
  • SYBX 43.75

About KAPA KAIROS PHARMA LTD

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: